Wellstar’s Center for Health Transformation (CHT) has made a strategic equity investment in Sensiotec, marking the first direct investment by CHT in a health technology company, and expands the technical and go-to-market collaboration that exists between the two parties.

In conjunction with the investment, CHT will deploy Sensiotec’s Virtual Medical Assistant (VMA) in diverse clinical settings, such as sleep labs, long term care residential care, post-hospital discharge home care and pediatric units, for a variety of uses. VMA is a radar-based biosensing platform, and the world’s first FDA 510k Class II-cleared, truly non-contact, patient monitoring solution. The technology enables it to capture large data sets over extended periods of time to identify cardiorespiratory instability, bed fall risk, patient agitation and pressure ulcers.

Recognized as the fifth most integrated healthcare delivery system in the U.S., WellStar Health System is the largest not-for-profit health system in Georgia and serves a population of more than 1.4 million residents in five counties.

CHT’s strategic investment in Sensiotec stemmed from the organization’s evaluation of 60 technology companies, all of which competed for the opportunity to team with WellStar. Sensiotec was selected based on the VMA’s potential to improve clinical outcomes and reduce costs across the care continuum, whether for a patient in the hospital, in long-term care or at home.